Journal
EPILEPSY & BEHAVIOR REPORTS
Volume 12, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ebr.2019.100341
Keywords
Cannabidiol (CBD); Treatment-resistant epilepsy (IRE); Voxel-based morphometry (VBM); Cortical thickness; Seizure frequency
Categories
Funding
- Alabama Department of Commerce
Ask authors/readers for more resources
Cannabis use is associated with changes in brain structure and function; its neurotoxic effects are largely attributed to Delta(9)-tetrahydrocannabidiol. Whether such effects are present in patients with epilepsy exposed to a highly-purified cannabidiol isolate (CBD; Epidiolex (R): Greenwich Biosciences, Inc.) has not been investigated to date. This preliminary study examines whether daily CBD dose of 15-25 mg/kg produces cerebral macrostructure changes and, if present, how they relate to changes in seizure frequency. Twenty-seven patients with treatmentresistant epilepsy were recruited from the University of Alabama at Birmingham CBD Program. Participants provided seizure frequency diaries (SF), completed the Chalfont Seizure Severity Scale (CSSS) and Adverse Events Profile (AEP), and underwent MRI before CBD (baseline) and after achieving a stable CBD dosage (on-CBD). We examined T1 -weighted structural images for gray matter volume (GMV) and cortical thickness changes from baseline to on-CBD in 18 participants. Repeated measures t-tests confirmed decreases in SF [t(17) = 3.08, p = 0.0069], CSSS [t(17) = 5.77, p < 0.001], and AEP [t(17) = 3.04, p = 0.0074] between the two timepoints. Voxel-level paired samples t-tests did not identify significant changes in GMV or cortical thickness between these two time-points. In conclusion, short-term exposure to highly purified CBD may not affect cortical macrostructure. (C) 2019 The Authors. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available